 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| Napatrin (ketamine/sufentanil) / Cessatech
Trial completion date, Trial primary completion date: Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients (clinicaltrials.gov) - Nov 7, 2024
P2/3, N=150, Recruiting, Sponsor: Cessatech A/S
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
- |||| Napatrin (ketamine/sufentanil) / Cessatech
Enrollment open: Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients (clinicaltrials.gov) - May 29, 2024
P2/3, N=150, Recruiting, Sponsor: Cessatech A/S
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024 Not yet recruiting --> Recruiting
- |||||||| Napatrin (ketamine/sufentanil) / Cessatech
New P2/3 trial: Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients (clinicaltrials.gov) - Apr 14, 2024
P2/3, N=150, Not yet recruiting, Sponsor: Cessatech A/S
- ||||||| Napatrin (ketamine/sufentanil) / Cessatech
Trial completion: Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 (clinicaltrials.gov) - Oct 18, 2023
P2/3, N=220, Completed, Sponsor: Cessatech A/S
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| Napatrin (ketamine/sufentanil) / Cessatech
Trial completion date, Trial primary completion date: Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 (clinicaltrials.gov) - May 11, 2023
P2/3, N=220, Recruiting, Sponsor: Cessatech A/S
Recruiting --> Completed Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023
- |||||| Napatrin (ketamine/sufentanil) / Cessatech
Enrollment open: Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 (clinicaltrials.gov) - Oct 3, 2022
P2/3, N=220, Recruiting, Sponsor: Cessatech A/S
Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023 Not yet recruiting --> Recruiting
- |||||||||| Napatrin (ketamine/sufentanil) / Cessatech
New P2/3 trial: Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 (clinicaltrials.gov) - Aug 19, 2022
P2/3, N=220, Not yet recruiting, Sponsor: Cessatech A/S
- || Napatrin (ketamine/sufentanil) / Cessatech
Trial completion: Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures (clinicaltrials.gov) - Aug 18, 2022
P2, N=25, Completed, Sponsor: Cessatech A/S
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Napatrin (ketamine/sufentanil) / Cessatech
Trial primary completion date: Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures (clinicaltrials.gov) - Jan 14, 2022
P2, N=25, Recruiting, Sponsor: Cessatech A/S
Recruiting --> Completed Trial primary completion date: Dec 2021 --> Mar 2022
- || Napatrin (ketamine/sufentanil) / Cessatech
Trial completion: Study of CT001 in Healthy Volunteers (clinicaltrials.gov) - Aug 23, 2021
P1, N=14, Completed, Sponsor: Cessatech A/S
Trial primary completion date: Dec 2021 --> Mar 2022 Recruiting --> Completed
- || Napatrin (ketamine/sufentanil) / Cessatech
Enrollment open: Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures (clinicaltrials.gov) - Jul 5, 2021
P2, N=25, Recruiting, Sponsor: Cessatech A/S
Recruiting --> Completed Not yet recruiting --> Recruiting
- || Napatrin (ketamine/sufentanil) / Cessatech
New P2 trial: Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures (clinicaltrials.gov) - May 20, 2021
P2, N=25, Not yet recruiting, Sponsor: Cessatech A/S
- || Napatrin (ketamine/sufentanil) / Cessatech
Enrollment open: Study of CT001 in Healthy Volunteers (clinicaltrials.gov) - May 13, 2021
P1, N=12, Recruiting, Sponsor: Cessatech A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Napatrin (ketamine/sufentanil) / Cessatech
New P1 trial: Study of CT001 in Healthy Volunteers (clinicaltrials.gov) - Mar 19, 2021
P1, N=12, Not yet recruiting, Sponsor: Cessatech A/S